Genentech, Inc. et al v. Aurobindo Pharma Limited et al
| Genentech, Inc. and InterMune, Inc. |
| Aurobindo Pharma USA, Inc. and Aurobindo Pharma Limited |
| 1:2019cv00103 |
| January 17, 2019 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on March 13, 2019. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 12 ANSWER to #10 Answer to Complaint, and Counterclaims, by Genentech, Inc., InterMune, Inc..(Blumenfeld, Jack) Modified on 3/13/2019 (nms). |
| Pro Hac Vice Attorneys Ryan Hagglund, Warren K. MacRae, and Mark E. Waddell for Genentech, Inc. and InterMune, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-00078-RGA et al.(ddp) |
| Filing 11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma USA, Inc. for Aurobindo Pharma Limited filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Filing 10 ANSWER to #1 Complaint, , COUNTERCLAIM against Genentech, Inc., InterMune, Inc. by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited.(Dorsney, Kenneth) |
SO ORDERED, re (11 in 19-cv-78-RGA, 8 in 19-cv-154-RGA, 7 in 19-cv-202-RGA, 8 in 19-cv-130-RGA, 9 in 19-cv-103-RGA, 9 in 19-cv-110-RGA, 9 in 19-cv-123-RGA, 8 in 19-cv-205-RGA, 8 in 19-cv-219-RGA, 10 in 19-cv-178-RGA, 13 in 19-cv-131-RGA, 7 in 19-cv-223-RGA, 7 in 19-cv-142-RGA, 7 in 19-cv-136-RGA, 11 in 19-cv-104-RGA, 8 in 19-cv-190-RGA, 7 in 19-cv-141-RGA, 8 in 19-cv-177-RGA, 13 in 19-cv-132-RGA, 9 in 1:19-cv-00120-RGA, 8 in 19-cv-111-RGA, 8 in 19-cv-195-RGA, 9 in 19-cv-105-RGA, 9 in 1:19-cv-00109-RGA, 7 in 19-cv-203-RGA, 10 in 19-cv-164-RGA) MOTION for Pro Hac Vice Appearance of Attorney Mark E. Waddell, Warren K. MacRae and Ryan Hagglund of LOEB & LOEB LLP filed by Genentech, Inc., InterMune, Inc.. Signed by Judge Richard G. Andrews on 2/12/2019. Associated Cases: 1:19-cv-00078-RGA et al.(nms)
|
| Filing 9 MOTION for Pro Hac Vice Appearance of Attorney Mark E. Waddell, Warren K. MacRae and Ryan Hagglund of LOEB & LOEB LLP - filed by Genentech, Inc., InterMune, Inc.. (Jacobs, Karen) |
| Filing 8 STIPULATION TO EXTEND TIME for Defendants Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. to answer, move or otherwise respond to the Complaint to February 20, 2019 - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
|
SO ORDERED, re (8 in 19-cv-103-RGA, 8 in 19-cv-105-RGA) STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to February 20, 2019. Signed by Judge Richard G. Andrews on 1/29/2019. Associated Cases: 1:19-cv-00103-RGA, 1:19-cv-00105-RGA(nms)
|
| Filing 7 DECLARATION of Mailing, by Genentech, Inc., InterMune, Inc.. (Blumenfeld, Jack) Modified on 1/24/2019 (nms). |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:19-cv-00103-RGA through 1:19-cv-00105-RGA and 1:19-cv-00109-RGA through 1:19-cv-00111-RGA (rjb) |
| Filing 6 SUMMONS Returned Executed by InterMune, Inc., Genentech, Inc.. Aurobindo Pharma USA, Inc. served on 1/18/2019, answer due 2/8/2019. (Blumenfeld, Jack) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Genentech, Inc. for InterMune, Inc.; Corporate Parent Roche Holdings Ltd., Corporate Parent Novartis Ltd., Corporate Parent Roche Holdings, Inc. for Genentech, Inc. filed by Genentech, Inc., InterMune, Inc.. (ddp) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s)- See Attached. (ddp) Modified on 1/17/2019 (ddp). |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/12/2018. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 4/15/2022. (ddp) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (ddp) |
| Filing 1 COMPLAINT for Patent Infringement filed against Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2547076.) - filed by InterMune, Inc., Genentech, Inc.. (Attachments: #1 Exhibit 1-19, #2 Civil Cover Sheet)(ddp) Modified on 1/17/2019 (ddp). |
| Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma Limited on 1/17/2019; Aurobindo Pharma USA, Inc. on 1/17/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (ddp) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
